FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma

CompletedOBSERVATIONAL
Enrollment

66

Participants

Timeline

Start Date

September 7, 2017

Primary Completion Date

October 4, 2019

Study Completion Date

October 4, 2019

Conditions
LymphomaLymphoma, Non-HodgkinLarge B Cell Diffuse Lymphoma
Interventions
DIAGNOSTIC_TEST

FLT-PET/CT

Standard of Care

DIAGNOSTIC_TEST

FDG-PET/CT

Standard of Care

DRUG

FLT

5 mCi IV

Trial Locations (4)

77030

MD Anderson Cancer Center - University of Texas, Houston

90024

University of California at Los Angeles, Los Angeles

68198-7680

University of Nebraska Medical Center, Omaha

Unknown

Aachen University, Aachen

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

Jonsson Comprehensive Cancer Center

OTHER

NCT01410630 - FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma | Biotech Hunter | Biotech Hunter